Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma.

Abstract

INTRODUCTION:

Peripheral T cell lymphomas (PTCL) are a group of heterogenous hematologic malignancies derived from post-thymic T lymphocytes and mature NK cells. Conventional chemotherapy does not guarantee a good outcome.

AREAS COVERED:

The article summarizes recent investigational therapies and their mechanism of action, as well as the pharmacological properties, clinical activity, and toxicity of new agents in the treatment of primary nodal PTCLs. The review scrutinized papers included in the MEDLINE (PubMed) database between 2010 and October 2020. These were supplemented with a manual search of conference proceedings from the previous five years of the American Society of Hematology, European Hematology Association, and American Society of Clinical Oncology. Further relevant publications were obtained by reviewing the references from the chosen articles.

EXPERT OPINION:

PTCLs have proved difficult to treat and investigate because of their rarity. Studies of aggressive lymphoma, including a small proportion of T-cell lymphomas, found that any benefit from intensified traditional chemotherapy in patients with PTCL is accompanied by increased toxicity. However, the management of PTCL is beginning to change dramatically, thanks to the use of more sophisticated agents targeting the mechanisms of disease development.

• Authors: Anna Wolska-Washer, Piotr Smolewski, Tadeusz Robak
• Journal: Expert opinion on pharmacotherapy (Expert Opin Pharmacother) Vol. 22 Issue 9 Pg. 1203-1215 (Jun 2021) ISSN: 1744-7666 [Electronic] England
• PMID: 33524268 (Publication Type: Journal Article)

Topics

• Humans
• Lymphoma, T-Cell, Peripheral (drug therapy)